New blood test for prostate cancer diagnosticsCategories: Artikkelit
Docrates Cancer Center is first in Finland to start using a new blood test supporting PSA-testing in prostate cancer
A new blood test, Proclarix, is useful in situations where the patient’s PSA level is slightly elevated and there is not full certainty of cancer tumor in the prostate.
– Proclarix test gives more exact information of the situation. We can then use other treatments if needed, i.e. biopsy and imaging, says Ph.D., Adj. Prof. Timo Joensuu, Specialist in Medical Oncology and Radiotherapy, expert in prostate cancer treatments.
-The new blood test alongside with PSA testing is for example assisting in detecting situations where the patient is having an enlarged prostate and not cancer. If no biopsy is needed, the patient will spare time, inconvenience and also costs.
If a biopsy still has to be made, it can be executed by robot-assisted MRI-guided biopsy at Docrates Cancer Center. The method allows taking local and exact biopsies of the prostate.
If you need additional information about diagnostics or treatments of prostate cancer at Docrates Cancer Center, please contact our personnel +358 10 773 2010.
Proclarix can be used in situations to diagnose prostate cancer in which the patient’s PSA level is elevated (2-10 ng/ml), and the prostate enlarged. Proclarix test gives a risk value which has been proved in studies making clinically significant evidence of prostate cancer. The blood test is validated in international studies.
More information about the latest diagnostics in prostate cancer treatments.
Klocker H. et al. Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass 2020;1: 15-20, DOI: 10.1002/bco2.8
Endt K. et al. Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE 12(8): e0181557. DOI: 10.1371/journal.pone.0181557
Steuber T. et al. Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unneeded prostate biopsies. BJU Int 2019; 123: 826–833. DOI:10.1111/bju.14540
Pye H. et al. Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. J Clin Oncol 2020 38(6_suppl), 278-278, DOI: 10.1200/JCO.2020.38.6_suppl.278